GMCI plus Standard of Care Immune Checkpoint Inhibitor

Recruiting

18 years - 99 years

All

Phase N/A

10 participants needed

1 Location

Brief description of study

This trial is to evaluate the safety and efficacy of adding GMCI to standard of care in patients with stage III/IV NSCLC that are not responding to a first line immune checkpoint inhibitor (ICI).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Non Small Lung Cancer,Non Small Lung Cancer
Age: 18 years - 99 years
Gender: All

Male or Female 18 years of age or older Non Small Lung cancer

Updated on 04 Aug 2024. Study ID: 844087

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

GMCI plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients (LuTK02)

Brief description of study

Eligibility of study

Find a site

Interested in the study